REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company focused on advancing precision oncology through biomarker innovation, announced today the presentation of seven studies at the upcoming ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in ...

Enhertu (trastuzumab Deruxtecan [T-DXd]) treated patients continue to be eligible for enrollment in FLAMINGO-01. The Company believes that GLSI-100 will synergize with any trastuzumab based treatment ...

An update from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) is now available. Shanghai Henlius Biotech, Inc. announced that its product, ...

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and ...

The clinical stage oncology company said Friday that data for the drug enozertinib, or ORIC-114, showed promising safety and activity in HER2‑mutant non-small cell lung cancer, especially at an 80 ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial of ...

Celcuity has successfully transitioned from a speculative biotechnology company to a pre-commercial firm with a de-risked ...

Learn more about whether Ultragenyx Pharmaceutical Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor ...

Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with ...

Drs Kathy Miller and Alexandra Thomas discuss important toxicities for breast cancer HER2-targeted therapies and how to ...